Michael Dore
Stephen R. Buckingham
LOWENSTEIN SANDLER, PC
65 Livingston Avenue
Roseland, New Jersey 07068
Tel.: (973) 597-2500

Attorneys for Plaintiffs Purdue Pharmaceutical Products L.P., Purdue Pharma L.P., and Transcept Pharmaceuticals, Inc.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

PURDUE PHARMACEUTICAL PRODUCTS L.P., PURDUE PHARMA L.P., and TRANSCEPT PHARMACEUTICALS, INC., Plaintiffs, v. PAR PHARMACEUTICAL, INC., Defendant.	Civil Action No. _____ Document Filed Electronically

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs Purdue Pharmaceutical Products L.P.; Purdue Pharma L.P.; and Transcept Pharmaceuticals, Inc. (collectively, "Plaintiffs"), by their attorneys, for their complaint against Par Pharmaceutical, Inc. ("Par") allege as follows:

The Parties

1. Plaintiff Purdue Pharmaceutical Products L.P. is a limited partnership organized and existing under the laws of Delaware with its principal place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

2. Plaintiff Purdue Pharma L.P. is a limited partnership organized and existing under the laws of Delaware with its principal place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

3. Plaintiff Transcept Pharmaceuticals, Inc. is a corporation organized and existing under the laws of Delaware with its principal place of business at 1003 W. Cutting Blvd., Suite #110, Pt. Richmond, CA 94804.

4. Upon information and belief, Defendant Par Pharmaceutical, Inc. is a corporation organized and existing under the laws of Delaware with its principal place of business at 1 Ram Ridge Rd., Spring Valley, NY 10977.

5. Upon information and belief, Defendant Par is in the business of developing, manufacturing, and distributing generic pharmaceutical products throughout the United States, including in this judicial district. Upon information and belief, Par has a least one place of business in New Jersey, and is registered to do business in New Jersey under Business I.D. No. 0100071541. Upon information and belief, Par is also a registered manufacturer and wholesaler of drugs in New Jersey, with Registration Nos. 5001143 (manufacturer) and 5004032 (manufacturer and wholesaler). Upon information and belief, the CEO and Chairman of the Board of Defendant Par is located in Woodcliff Lake, New Jersey. Upon information and belief, Par shares a CEO and Board Chairman with parent company Par Pharmaceutical Companies, Inc., which has its principal place of business in Woodcliff Lake, New Jersey.

Jurisdiction and Venue

6. This is a civil action for patent infringement arising under the patent laws of the United States, Title 35 of the U.S. Code, for infringement of U.S. Patent No. 8,242,131 (the "'131 Patent") and U.S. Patent No. 8,252,809 (the "'809 Patent").

7. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

8. This Court has personal jurisdiction over Par by virtue of its widespread and continuous contacts with the state of New Jersey. Among other things, upon information and belief, Par has at least one business location in New Jersey and is registered to do business in New Jersey under Business I.D. No. 0100071541. Upon information and belief, Par is also a registered manufacturer and wholesaler of drugs in New Jersey, with Registration Nos. 5001143 (manufacturer) and 5004032 (manufacturer and wholesaler). Upon information and belief the CEO and Chairman of the Board of Par is located in Woodcliff Lake, New Jersey.

9. Par has previously submitted to, and purposefully availed itself of, the jurisdiction of the U.S. District Court for the District of New Jersey, including by filing counterclaims in this Court. *See, e.g.*, *Medeva Pharma Suisse A.G. et al. v. Par Pharm., Inc. et al.*, 3:10-cv-04008 (D.N.J.) (D.I. No. 11) (counterclaim filed by Par); *Abbott Labs. et al. v. Par Pharm. Inc.*, 2:04-cv-00325 (D.N.J.) (D.I. No. 4) (same); *Hoechst Marion v. Par Pharm. Inc.*, 2:95-cv-03673 (D.N.J.) (D.I. No. 16) (same).

10. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391 and 1400(b).

Regulatory Requirements for New and Generic Drugs

11. A person wishing to market a new drug that has not previously been approved by the U.S. Food and Drug Administration ("FDA") (a "pioneering" drug) must file a New Drug Application ("NDA") with FDA demonstrating that the drug is safe and effective for its intended use. 21 U.S.C. § 355(b).

12. A person wishing to market a generic copy of a drug that previously has been approved by FDA may follow a truncated approval process by filing an Abbreviated New Drug Application ("ANDA") for a generic version of that drug. In the ANDA, the applicant must demonstrate, among other things, bioequivalence of the generic copy with the pioneering drug. 21 U.S.C. § 355(j)(2)(A)(iv).

13. Unlike an NDA applicant, an ANDA applicant is not required to include safety and effectiveness data. Instead, the ANDA applicant is permitted to rely on the approval of the NDA applicant's drug—in essence, piggybacking on the NDA application and safety and effectiveness conclusions. 21 U.S.C. § 355(j).

14. Nor does an ANDA applicant establish any new conditions of use for the proposed drug product. Instead, an ANDA applicant may seek approval only for conditions of use that previously have been approved in connection with an approved NDA. 21 U.S.C. § 355(j)(2)(A)(i).

The Approved Drug Product

15. Purdue Pharmaceutical Products L.P. is the current holder of NDA No. 022328, for sublingual tablets containing 1.75 mg and 3.5 mg of zolpidem tartrate, which was first approved by FDA on November 23, 2011. Purdue Pharma L.P. markets the approved drug product under the tradename INTERMEZZO®. INTERMEZZO® is approved for treatment of insomnia when middle-of-the-night awakening is followed by difficulty returning to sleep. A copy of the prescribing information for INTERMEZZO® approved in NDA No. 022328 is attached as Exhibit A.

16. FDA has listed U.S. Patent Nos. 8,242,131 and 8,252,809 in the Orange Book—formally known as *Approved Drug Products With Therapeutic Equivalence Evaluations*—in connection with NDA No. 022328.

17. Transcept Pharmaceuticals, Inc. is the owner of the '131 and '809 Patents. Purdue Pharma L.P. and Purdue Pharmaceutical Products L.P. are exclusive licensees under the '131 and '809 Patents, the former to sell or offer to sell, and the latter to manufacture, zolpidem tartrate sublingual tablets.

ANDA No. 204229

18. Upon information and belief, on or before September 10, 2012, Par submitted to FDA an ANDA (ANDA No. 204229) with paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. § 355(j)(2)(A)(vii)(IV), for 1.75 mg and 3.5 mg zolpidem tartrate sublingual tablets purportedly bioequivalent to INTERMEZZO®. The purpose of the ANDA is to obtain approval under section 505(j) of the FDCA to engage in the commercial manufacture and sale of a generic INTERMEZZO® product.

19. Upon information and belief, the indication set forth in the proposed labeling submitted in ANDA No. 204229 for Par's generic INTERMEZZO® product is the treatment of insomnia when middle-of-the-night awakening is followed by difficulty returning to sleep, *i.e.*, the same indication as that set forth in the approved labeling for INTERMEZZO®.

20. Upon information and belief, Par sent Plaintiffs Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. a letter dated September 10, 2012 (the "Notice Letter"). The Notice Letter represented that Par had submitted to FDA ANDA No. 204229 with paragraph IV certifications for the '131 and '809 Patents.

21. Upon information and belief, the purpose of the ANDA and paragraph IV certifications is to obtain approval under section 505(j) of the FDCA to engage in the commercial manufacture and sale of a generic version of INTERMEZZO® before the expiration of the patents listed in the Orange Book for NDA No. 022328. Hence, Par's purpose in submitting ANDA No. 204229 is to market the product described therein before expiration of the '131 and '809 Patents.

Count 1: Patent Infringement of the '131 Patent

22. Plaintiffs incorporate by reference all the allegations contained in paragraphs 1 to 21 above.

23. United States Patent No. 8,242,131, entitled "METHODS OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA," was duly and legally issued by the United States Patent and Trademark Office on August 14, 2012. Plaintiff Transcept Pharmaceuticals, Inc. is the owner of the '131 Patent. Plaintiffs Purdue Pharmaceutical Products L.P. and Purdue Pharma L.P. are exclusive licensees of the '131 Patent. A true and complete copy of the '131 Patent is attached hereto as Exhibit B.

24. Upon information and belief, Par submitted ANDA No. 204229 to FDA seeking approval to engage in the commercial manufacture, use, offer for sale, and sale of a generic version of INTERMEZZO® before the expiration of the '131 Patent.

25. Par's manufacture, use, offer for sale, or sale of such product would infringe the claims of the '131 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

26. Upon information and belief, if approved, the generic INTERMEZZO® product for which approval is sought in Par's ANDA No. 204229 will be administered to human patients for the treatment of insomnia when middle-of-the-night awakening is followed by difficulty

returning to sleep, which administration would constitute direct infringement, either literally or under the doctrine of equivalents, of one or more claims of the '131 Patent. Upon information and belief, this infringement will occur at Par's behest, with its intent, knowledge, and encouragement, and Par will actively induce, encourage, aid and abet this administration with knowledge that it is in contravention of Plaintiffs' rights under the '131 Patent.

27. Par's manufacture, use, offer for sale, or sale in the United States, or importation into the United States, of the generic INTERMEZZO® product for which approval is sought in ANDA No. 204229 would actively induce and contribute to infringement of the '131 Patent, and Par would be liable as an infringer under 35 U.S.C. § 271(b) and/or (c).

28. Upon information and belief, as part of the ANDA filing, Par purportedly provided written certification to FDA that the claims of the '131 Patent are invalid and/or will not be infringed by the manufacture, use, or sale of Par's generic version of INTERMEZZO®.

29. Upon information and belief, by letter dated September 10, 2012, Par gave written notice of its certification of invalidity and/or non-infringement of the '131 Patent, alleging that all claims of the '131 Patent are invalid, and informing Plaintiffs that Par seeks approval to engage in the commercial manufacture, use, and sale of a product bioequivalent to INTERMEZZO® prior to the expiration of the '131 Patent.

30. Par has infringed the '131 Patent under 35 U.S.C. § 271(e)(2)(A) by virtue of submitting ANDA No. 204229 to market a generic version of INTERMEZZO® prior to the expiration of the '131 Patent. Moreover, if Par commercially uses, offers for sale, or sells its generic version of INTERMEZZO®, or induces or contributes to such conduct, it would further infringe the '131 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

31. This case is an exceptional one, and Plaintiffs are entitled to an award of their reasonable attorneys' fees under 35 U.S.C. § 285.

32. Plaintiffs will be irreparably harmed if Defendant is not enjoined from infringing or actively inducing or contributing to infringement of the '131 Patent. Plaintiffs do not have an adequate remedy at law.

Count 2: Patent Infringement of the '809 Patent

33. Plaintiffs incorporate by reference all the allegations contained in paragraphs 1 to 32 above.

34. United States Patent No. 8,252,809, entitled "COMPOSITIONS FOR TREATING INSOMNIA," was duly and legally issued by the United States Patent and Trademark Office on August 28, 2012. Plaintiff Transcept Pharmaceuticals, Inc. is the owner of the '809 Patent. Plaintiffs Purdue Pharmaceutical Products L.P. and Purdue Pharma L.P. are exclusive licensees of the '809 Patent. A true and complete copy of the '809 Patent is attached hereto as Exhibit C.

35. Upon information and belief, Par submitted ANDA No. 204229 to FDA seeking approval to engage in the commercial manufacture, use, offer for sale, and sale of a generic version of INTERMEZZO® before the expiration of the '809 Patent.

36. Par's manufacture, use, offer for sale, or sale of such product would infringe the claims of the '809 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

37. Upon information and belief, if approved, the generic INTERMEZZO® product for which approval is sought in Par's ANDA No. 204229 will be administered to human patients for the treatment of insomnia when middle-of-the-night awakening is followed by difficulty returning to sleep, which administration would constitute direct infringement, either literally or

under the doctrine of equivalents, of one or more claims of the '809 Patent. Upon information and belief, this infringement will occur at Par's behest, with its intent, knowledge, and encouragement, and Par will actively induce, encourage, aid and abet this administration with knowledge that it is in contravention of Plaintiffs' rights under the '809 Patent.

38. Par's manufacture, use, offer for sale, or sale in the United States, or importation into the United States, of the generic INTERMEZZO® product for which approval is sought in ANDA No. 204229 would actively induce and contribute to infringement of the '809 Patent, and Par would be liable as an infringer under 35 U.S.C. § 271(b) and/or (c).

39. Upon information and belief, as part of the ANDA filing, Par purportedly provided written certification to FDA that the claims of the '809 Patent are invalid and/or will not be infringed by the manufacture, use, or sale of Par's generic version of INTERMEZZO®.

40. Upon information and belief, by letter dated September 10, 2012, Par gave written notice of its certification of invalidity and/or non-infringement of the '809 Patent, alleging that all claims of the '809 Patent are invalid, and informing Plaintiffs that Par seeks approval to engage in the commercial manufacture, use, and sale of a product bioequivalent to INTERMEZZO® prior to the expiration of the '809 Patent.

41. Par has infringed the '809 Patent under 35 U.S.C. § 271(e)(2)(A) by virtue of submitting ANDA No. 204229 to market a generic version of INTERMEZZO® prior to the expiration of the '809 Patent. Moreover, if Par commercially uses, offers for sale, or sells its generic version of INTERMEZZO®, or induces or contributes to such conduct, it would further infringe the '809 Patent under 35 U.S.C. § 271(a), (b), and/or (c).

42. This case is an exceptional one, and Plaintiffs are entitled to an award of their reasonable attorneys' fees under 35 U.S.C. § 285.

43. Plaintiffs will be irreparably harmed if Par is not enjoined from infringing or actively inducing or contributing to infringement of the '809 Patent. Plaintiffs do not have an adequate remedy at law.

Prayer for Relief

WHEREFORE, Plaintiffs seek the following relief:

A. A judgment that Par has infringed the '131 and '809 Patents under 35 U.S.C. § 271(e)(2)(A);

B. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any approval of ANDA No. 204229 is not earlier than the latest expiration date of the '131 and '809 Patents, or any later expiration of exclusivity for the '131 or '809 Patent to which Plaintiffs are or become entitled;

C. A permanent injunction restraining and enjoining Par and its officers, agents, servants, employees, parents, subsidiaries, divisions, affiliates, and those persons in active concert or participation with any of them, from making, using, selling, offering to sell, or importing any product that infringes the '131 or '809 Patent, including the product described in ANDA No. 204229;

D. A judgment declaring that the making, using, selling, offering to sell, or importing of the product described in ANDA No. 204229, or inducing or contributing to such conduct, would constitute infringement of the '131 and '809 Patents by Par pursuant to 35 U.S.C. § 271(a), (b), and/or (c);

E. A finding that this is an exceptional case, and an award of attorneys' fees in this action pursuant to 35 U.S.C. § 285;

F. Costs and expenses in this action; and

G. Such further and other relief as this Court determines to be just and proper.

Dated: October 25, 2012

Respectfully submitted,

/s/ Michael Dore
Michael Dore
Stephen R. Buckingham
LOWENSTEIN SANDLER, PC
65 Livingston Avenue
Roseland, N.J. 07068
Tel: (973) 597-2500

Attorneys for Plaintiffs Purdue Pharmaceutical Products L.P., Purdue Pharma L.P., and Transcept Pharmaceuticals, Inc.

Of Counsel:
Christopher N. Sipes
Michael N. Kennedy
Erica N. Andersen
COVINGTON & BURLING LLP
1201 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel: (202) 662-6000

NOTICE OF OTHER ACTIONS PURSUANT TO L. CIV. R. 11.2

The undersigned hereby certifies that the matter in controversy is not the subject of any other action or proceeding in any court or of a pending arbitration proceeding, except that the same FDA-approved pharmaceutical drug product on which this Complaint is based is the subject of three other patent infringement actions involving a patent that is not at issue in this action, all of which are currently pending in this District and assigned to the same District Judge: *Purdue Pharmaceutical Products, Inc. et al. v. Actavis Elizabeth LLC*, 2:12-cv-5311-JLL-MAH; *Purdue Pharmaceutical Products, Inc. et al. v. Watson Pharmaceuticals, Inc. et al.*, 2:12-cv-5390-JLL-MAH; and *Purdue Pharmaceutical Products, Inc. et al. v. Novel Laboratories, Inc.*, 2:12-cv-5650-JLL-MAH. In addition, contemporaneously with the filing of this Complaint, Plaintiffs are also filing another Complaint based on the same United States Patents asserted in this case, *Purdue Pharmaceutical Products, Inc. et al. v. Par Formulations Private, Ltd.*, which has not yet been assigned a docket number or been assigned to a District Judge.

/s/ Michael Dore
Michael Dore
LOWENSTEIN SANDLER, PC
65 Livingston Avenue
Roseland, N.J. 07068
Tel: (973) 597-2500